The recommended screening mode includes clinical and anamnestic evaluation, a hormone study of the hypothalamic–pituitary–ovarian axis (FSH, LH; estradiol, progesterone, prolactin), a gynaecological examination, a pelvic ultrasound and a hysterosalpingography, a PAP test, and an exclusion of sexually transmitted infections. Here, BRD2 is linked to sexually transmitted disease.